ALEXANDRIA, Va., Jan. 28 -- United States Patent no. 12,534,532, issued on Jan. 27, was assigned to CRAGE MEDICAL Co. Ltd. (Hong Kong).
"CLL1-targeting antibody and application thereof" was invented by Zonghai Li (Shanghai), Peng Wang (Shanghai) and Huamao Wang (Shanghai).
According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are a CLL1-targeting antibody and an application thereof. The CLL1-specific antibody has high affinity for CLL1, and after being prepared into a chimeric antigen receptor-modified T cells, has a significant killing effect on cells expressing CLL1."
The patent was filed on Oct. 28, 2019, under Application No. 17/288,189.
*For further information, including images, charts and tables, pl...